SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

STRO-004

STRO·Sutro Biopharma, Inc.
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 1
Time to market
Still in Phase 1 dose escalation; assuming successful Phase 1/2 and pivotal trials, potential approval would be several years away, likely 2029 or later.
Why 6/10
The next hard, dated catalyst is the next clinical update and initiation of expansion cohorts for the Phase 1 STRIVE-01 study, planned for the first half of 2027. This is roughly 6-12 months out and STRO-004 is Sutro's lead wholly-owned asset, but the company also has STRO-006 and other pipeline programs, so it is not a pure single-asset binary.
Actionable Insight NEUTRAL

The Phase 1 dose-escalation data from August 2026 showed early signals of activity (confirmed and unconfirmed partial responses) but also dose-limiting toxicities at the highest dose. The next update in H1 2027 will include expansion cohorts and more mature efficacy/safety data. Investors should watch for the dose selected for expansion, the durability of responses, and whether the safety profile supports a competitive advantage over the approved tissue-factor ADC Tivdak (tisotumab vedotin).

Price Chart

Loading chart...

Executive Summary

STRO-004 is Sutro Biopharma's lead wholly-owned asset, a next-generation antibody-drug conjugate targeting tissue factor (TF) for solid tumors. It entered Phase 1 (STRIVE-01) in late 2025 and early data from August 2026 showed some clinical activity (partial responses) but also dose-limiting toxicities at the highest dose. The next update with expansion cohorts is expected in the first half of 2027. Sutro has undergone major restructuring (reverse split, layoffs, management changes) and the stock trades around $9.73, far below the analyst mean price target of ~$47. The company faces competition from the approved TF-targeting ADC Tivdak (tisotumab vedotin, from Genmab/Pfizer) and has a cash runway into H1 2028. Analyst consensus is strongly bullish (18 buy/strong-buy ratings vs 2 hold/sell), but the stock has fallen sharply in 2026.

How It Works

STRO-004 is an antibody-drug conjugate (ADC) that targets tissue factor (TF), a protein found on the surface of many solid tumor cells. It is designed to deliver a potent chemotherapy drug (exatecan, a topoisomerase I inhibitor) directly to cancer cells. The antibody binds to TF on tumor cells, the ADC is absorbed, and the exatecan payload kills the cell from within. Sutro's version uses a high drug-to-antibody ratio of 8 (eight payload molecules per antibody) and its proprietary site-specific conjugation technology, aiming for better efficacy and tolerability than earlier TF-targeting ADCs.

Trial Status

The Phase 1 STRIVE-01 study is actively enrolling patients with advanced solid tumors in dose escalation. As of the Q3 2026 earnings release (November 12, 2026), the study is advancing and the next clinical update with expansion cohorts is planned for the first half of 2027. Early data from August 2026 showed confirmed and ongoing unconfirmed partial responses in heavily pretreated patients, with dose-limiting toxicities reported at the highest dose level.

The Two-Sided Case

▲ Bull Case5
Early Phase 1 data showed confirmed and ongoing unconfirmed partial responses in heavily pretreated patients with pancreatic, head and neck, and NSCLC cancers, suggesting clinical activity. (Source: Sutro Q2 2026 earnings press release, August 12, 2026)
The drug uses a high DAR-8 exatecan payload with Sutro's site-specific conjugation technology, which preclinical data suggested may offer improved efficacy versus benchmark TF-targeting ADCs. (Source: AACR 2026 preclinical data presentation, April 2026)
Analyst consensus is strongly bullish: 18 buy/strong-buy ratings, mean price target ~$47.23 vs current ~$9.73, implying roughly 390% upside.
Several tracked institutional investors added or doubled positions in Q3 2026, including FMR LLC (Fidelity), Qube Research, and JPMorgan.
Cash runway extends into H1 2028, providing a long development horizon without near-term dilution pressure. (Source: Sutro Q3 2026 earnings release, November 12, 2026)
▼ Bear Case6
Dose-limiting toxicities were reported at the highest dose level in the Phase 1 study, raising questions about the therapeutic window. (Source: Benzinga summary of August 2026 STRO-004 update)
The stock fell sharply after the August 2026 Phase 1 update, suggesting the market was not impressed by the early data. (Source: MSN/SeekingAlpha coverage, August 12, 2026)
Tivdak (tisotumab vedotin) from Genmab is already approved for recurrent cervical cancer, establishing a competitive benchmark that STRO-004 must beat on efficacy or safety. (Source: Medscape/ASCO publications)
Merck & Co. abandoned a Sutro-partnered IL-2 agonist in November 2026, a negative signal about the broader partnership ecosystem. (Source: FierceBiotech, November 6, 2026)
The stock has declined roughly 34-40% in the four weeks leading into November 2026, and short-sale volume is elevated relative to the stock's own history (z-score 1.8).
Sutro underwent a 1-for-10 reverse split in December 2025 to maintain Nasdaq compliance, a sign of prior financial distress. (Source: SeekingAlpha, May 2026)

Upcoming Catalysts

  • Next clinical update and initiation of expansion cohorts for the Phase 1 STRIVE-01 study, expected in the first half of 2027
  • Potential partnership or licensing interest in the TF-ADC platform
  • Q4 2026 earnings report (expected early 2027)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sutro Biopharma, Inc. PRESS-RELEASE STRO ·Originating report

Sources · 10

Hover a chip for the title
1 globenewswire.com2 globenewswire.com3 globenewswire.com4 globenewswire.com5 globenewswire.com6 msn.com7 seekingalpha.com8 fiercebiotech.com9 benzinga.com10 bioworld.com